Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation

Pediatric Transplantation

Volumn 17, Issue 8, 2013, Pages

  Sinibaldi, Serena ^a   Guzzo, Isabella ^a   Piras, Rossella ^b   Bresin, Elena ^b   Emma, Francesco ^a   Dello Strologo, Luca ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

hemolytic uremic syndrome; relapse; renal transplantation; THBD

Indexed keywords

BASILIXIMAB; ECULIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THROMBOMODULIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; GENE; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PERITONEAL DIALYSIS; PLASMAPHERESIS; RECURRENT DISEASE; THBD GENE; TREATMENT OUTCOME;

HEMOLYTIC UREMIC SYNDROME; RELAPSE; RENAL TRANSPLANTATION; THBD;

ANTIBODIES, MONOCLONAL, HUMANIZED; GRAFT REJECTION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; MALE; MUTATION; PLASMA EXCHANGE; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RENAL INSUFFICIENCY; STEROIDS; THROMBOMODULIN; YOUNG ADULT;

EID: 84886949690     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12151     Document Type: Article

References (24)

1. Noris M, Mescia F, Remuzzi G,. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012: 8: 622-633.
2. Noris M, Remuzzi G,. Hemolytic uremic syndrome. J Am Soc Nephrol 2005: 16: 1035-1050.
3. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012: 12: 3337-3354.
4. Loirat C, Noris M, Fremeaux-Bacchi V,. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008: 23: 1957-1972.
5. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013: 13: 663-675.
6. Delvaeye M, Noris M, de Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009: 361: 345-357.
7. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003: 12: 3385-3395.
8. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005: 14: 703-712.
9. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005: 16: 555-563.
10. Venables JP, Strain L, Routledge D, et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006: 3: e431.
11. Ohlin AK, Marlar RA,. Thrombomodulin gene defects in families with thromboembolic disease-a report on four families. Thromb Haemost 1999: 81: 338-344.
12. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010: 5: 1844-1859.
13. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background. Clin J Am Soc Nephrol 2006: 1: 88-99.
14. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ,. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010: 31: 1445-1460.
15. Loirat C, Fremeaux-Bacchi V,. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011: 6: 60.
16. Boehme MW, Deng Y, Raeth U, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: In vivo and in vitro studies. Immunology 1996: 87: 134-140.
17. Van de Wouwer M, Collen D, Conway EM,. Thrombomodulin-protein C-EPCR system: Integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004: 24: 1374-1383.
18. Esmon CT, Esmon NL, Conway EM,. Correspondence: Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2008: 361: 1511.
19. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013: 8: 554-562.
20. Bresin E, Rurali E, Caprioli J, et al. Combined complement gene mutations in aHUS: Impact on clinical phenotype. J Am Soc Nephrol 2013: 24: 475-486.
21. Noris M, Remuzzi G,. Atypical hemolytic uremic syndrome. N Engl J Med 2009: 361: 1676-1687.
22. Goicoechea de Jozrge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007: 104: 240-245.
23. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V,. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012: 8: 643-657.
24. Honda T, Ogata S, Mineo E, et al. A novel strategy for hemolytic uremic syndrome: Successful treatment with thrombomodulin alfa. Pediatrics 2013: 131: 928-933.